A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis.
The anti-fracture efficacy of sodium fluoride (NaF) was evaluated in 84 postmenopausal white women with spinal osteoporosis. The dose of NaF used was 75 mg/day and all patients in this prospective, randomized, double-blind, placebo-controlled clinical trial received calcium supplements (carbonate salt) 1500 mg/day in addition to participating in a structured physical therapy program. For each of the outcome measures (change in stature, change in cortical bone mass in the forearm and development of new vertebral fractures determined by change in vertebral morphometry and by scintigraphy) there was no significant difference between the fluoride or placebo treated groups. Side effects, predominantly gastrointestinal symptoms and the development of the painful lower extremity syndrome, occurred significantly more frequently in the fluoride group (P less than 0.05). Peripheral fractures were not more frequent in the fluoride group. We conclude that, in the dose and manner used in this study, NaF is no more effective than placebo in retarding the progression of spinal osteoporosis. There is no role for NaF in the treatment of osteoporosis outside the confines of clinical research.
Kleerekoper
M
M
Department of Internal Medicine, Henry Ford Hospital, Detroit, Michigan 48202.
Peterson
E L
EL
Nelson
D A
DA
Phillips
E
E
Schork
M A
MA
Tilley
B C
BC
Parfitt
A M
AM
D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D012969:Sodium Fluoride / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000517:prevention & control*
D012969:Sodium Fluoride